Picture EBD Group World of Partnering Opportunities 650x100px

Person › Details

Aram Mangasarian (Noxxon Pharma AG)

Mangasarian, Aram (Noxxon 201005 CBO before Novexel since 200511 VP BusDev before ExonHit VP BusDev)

	Organisation	Noxxon Pharma AG
	Today	TME Pharma AG
	Group	TME Pharma (Group)
	Former/major organisation	Novexel S.A.
	Group	AstraZeneca (Group)
	Product	Spiegelmer® product
	Product 2	Spiegelmer® technology

Record changed: 2023-01-25

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Aram Mangasarian

[1] TME Pharma N.V.. (1/23/23). "Press Release: TME Pharma Provides Clinical Update on the GLORIA Expansion Arm Testing NOX-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma". Berlin....
[2] Noxxon Pharma N.V.. (1/3/22). "Press Release: Noxxon Secures €17 Million Expansion of Equity-linked Facility with Atlas to Advance NOX-A12 in Glioblastoma and Pancreatic Cancer Programs [ corrected version of press release originally issued 29 Dec 2021 ...
[3] Noxxon Pharma N.V.. (10/27/21). "Press Release: Experienced Financial Executive, Bryan Jennings, Joins Noxxon as CFO". Berlin....
[4] Noxxon Pharma N.V.. (12/14/18). "Press Release: Noxxon Announces Key Findings that NOX-A12 plus Keytruda Induces an Immune Response and Results in Clinical Benefit for Patients". Berlin....
[5] Noxxon Pharma N.V.. (11/16/18). "Press Release: Noxxon Announces € 6.2 Million Equity Capital Raise including US$ 5 Million from US Family Office – Acuitas Capital, LLC. Noxxon Ends the Use of Variable Rate Equity Financing with Yorkville". Berlin....
[6] Noxxon Pharma N.V.. (10/23/18). "Press Release: Noxxon to Attend European Investor and Partnering Conferences in November 2018". Berlin....
[7] Noxxon Pharma N.V.. (6/15/18). "Press Release: Noxxon Announces that It Has Secured Additional Financing". Berlin....
[8] Noxxon Pharma N.V.. (10/3/17). "Press Release: Noxxon Publishes Preclinical Proof-of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors". Berlin....
[9] Noxxon Pharma N.V.. (9/28/17). "Press Release: Noxxon Provides Update on Ongoing Phase 1/2 Clinical Trial with Lead Program NOX-A12". Berlin....
[10] Noxxon Pharma N.V.. (7/11/17). "Press Release: Noxxon Pharma Announces Prospectus Publication and Share Transfer to the Public Offering Compartment of the EuroNext Growth Market". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]